

entX

Annual General Meeting

Friday, 23 May 2025



Managing Director Presentation

(Mr Bryn Jones)

Important Notice and Disclaimer

This Presentation is confidential and not for further distribution. It is provided on the basis that, by accepting it, persons to whom the Presentation is given agree to keep the information confidential, not copy the Presentation and not to disclose it, in whole or in part, to anyone within their organisation except on a need-to-know basis and subject to these restrictions, or to anyone outside their organisation.

By accepting this Presentation, you accept that this Presentation is provided on the terms and conditions of this notice. If any of the terms of this Important Notice and Disclaimer are not acceptable, you must immediately return this Presentation (and any copies of it, including the deletion of any electronic copies) to the Company, as defined below.

This Presentation

This Presentation has been prepared by and is the sole responsibility of EntX Limited (EntX or the Company). This Presentation has been prepared in relation to a company update. The information in this Presentation remains subject to change without notice. The information in this Presentation is of a general nature and does not purport to be accurate, reliable or complete, is provided solely for information purposes and should not be relied upon by you.

This Presentation is not intended to be and does not constitute a prospectus, short form prospectus or profile statement as those terms are defined in the Corporations Act 2001 (Cth) and does not contain the same degree or standard of information as a prospectus. The information in this Presentation is not an invitation to you or anyone else to purchase any securities in any jurisdiction.

No representation or warranty

While all reasonable efforts have been made to ensure the information contained in this Presentation is accurate and correct at the date of its issue, information contained in this Presentation has been derived from public sources and records maintained by the Company and has not been verified or assessed for accuracy or completeness by external advisers, intermediaries or independent experts, nor by any party who has distributed the Presentation on behalf of the Company.

No representation or warranty, express or implied is made by any person as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this Presentation. This Presentation does not purport to summarise all information that you should consider when making an investment decision, and should not form the basis of any decision by you. You should carry out their own investigations and analysis of the Company and verify the accuracy, reliability and completeness of the information contained in this Presentation or any other form of communication to which you are permitted access in the course of evaluating the Company.

Not financial product advice


Reliance should not be placed on the information or opinions contained in this Presentation. This Presentation is for informational purposes only and is not a financial product or investment advice, advice on legal, financial, taxation or investment matters or a recommendation to acquire any securities in the Company and does not take into consideration the investment objectives, financial situation or particular needs of any particular investor, or whether the information is sufficient or appropriate for any particular investors purposes, or contains all of the information that a prospective purchaser may require. You should conduct your own research into the financial condition, assets and liabilities, financial position and performance, profits and losses, prospects and business affairs of the Company and its business, and the contents of this Presentation. You should seek legal, financial, tax and other advice appropriate to your jurisdiction.

Past and future performance

Past performance information given in this Presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of future performance.

This Presentation contains certain forward-looking statements with respect to the financial condition, operations and business of the Company and certain plans and objectives of the Company. Forward-looking statements can be identified by the use of forward-looking terminology, including, without limitation, the terms “believes”, “estimates”, “anticipates”, “expects”, “predicts”, “intends”, “plans”, “targets”, “aims”, “outlook”, “guidance”, “forecasts”, “may”, “will”, “would”, “could” or “should” or, in each case, their negative or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that because of their nature may cause the actual results or performance of the Company to be materially different from the results or performance expressed or implied by such forward-looking statements.

Such forward-looking statements are based on numerous assumptions regarding the Company’s present and future business strategies and the political and economic environment in which the Company will operate in the future, which may not be reasonable, and are not guarantees or predictions of future performance. No representation is made that any of these statements or forecasts will come to pass or that any forecast result will be achieved, or that there is a reasonable basis for any of these statements or forecasts.



2024 – A Transformational Year



Space and Defence

- LOI signed to provide up to 48 RHUs by 2030
- Awarded a \$1M Australian Space Agency grant to launch RHUs and achieve flight heritage
- GenX performance reaches world leading power density output – now on the radar for Unmanned Underwater Vehicles (UUVs) to provide a unique capability enhancement



Medical Isotopes

- Completed Proof of Concept Yb-176 enrichment to feed the fast-growing Lu-177 industry
- Lab-scale production of Lead-212 precursor (Thorium-228) and began building supply capability
- Received \$1.9M Economic Recovery Fund grant for the construction of Australia's first commercial radioisotope production facility (ARPF)
- Awarded CRC-P grant (\$4.1m incl partner funding) to accelerate up-stream supply to the ARPF




Corporate

- Completed \$5.8M capital raise to advance technologies towards IPO ready
- Strengthened the team with several key hires
- Continued success in leverage shareholder funds with successful grants, R&D tax refunds and other funding leverage



Innovation and IP

- Strengthened the overall IP portfolio both in terms of successful granted patents and layering in new patents
- Continued development of additional commercialization pathways for the current IP portfolio



2025 – Platform set for commercialisation



Space and Defence

- Complete approvals for Q1 2026 RHU launch - build commercial contract book for lunar deployment
- Working with ispace (Japan) to integrate RHUs into their lunar lander
- Transform GenX production from lab scale to demonstration production scale by end CY 2025
- Deliver GenX units for customer validation and testing – progress to supply agreements
- Seek non-dilutive USA/Aus Defence funding to progress to commercial scale production



Medical Isotopes

- Isotope facility permitting and construction is underway
- Two off-take LOIs in place for Th-228 - advancing to commercial off-take agreements
- Processing current stockpile material to sale – developing larger scale supply capability
- Demonstration plant for Yb-176 production under construction – aiming for customer validation samples end of CY2025



Corporate


- Strong cash position heading into early-stage revenue 2H CY2025
- Strengthening valuation fundamentals through contract wins and delivery milestone achievements in Medical Isotopes and Space & Defence – Preparing for IPO readiness
- Strong sector support fundamentals in entX focus areas
- Further strengthening of the management team with key hires



Innovation and IP

- Additional leverage funding to develop alternative commercialization pathways for developed IP across the technology platforms
- Continued development of IP portfolio to protect key products and processes while being mindful of over disclosure

The platform technology and capabilities developed by entX will have application far beyond its current scope and projects creating the potential for future inorganic growth and licensing revenue



Growth Capital to Accelerate Opportunity Realisation



Following the successful capital raise in December 2024, entX has achieved a series of pivotal commercial and strategic milestones. These developments, combined with accelerating market interest globally, create a compelling case to raise an additional \$5 million to fast-track execution and first mover advantage of its platform technologies.

Key Developments



Telix Letter-of-Intent (Pb-212)



A Letter-of-Intent (LOI) signed with **Telix Pharmaceuticals (ASX:TLX)** with a formal offtake agreement for the provision of Thorium-228 and Ra-226 expected shortly. entX intends to **supply into this agreement in CY2025**.



Validates Thorium-228 production capability and de-risks IsoMedica's revenue pipeline for Pb-212. **Significantly increases the market opportunity for entX in the short term.**



MoU signed with ispace (RHU)



entX and ispace (Japan) collaboration to further develop, test and demonstrate the Company's RHU technology capability and integration in a lunar environment. **Provides an additional commercial pathway to deployment.**



Strengthens international partnerships and accelerates the commercialisation of the RHU technology.



Surging US interest in Betavoltaics (GenX)



Significant sector opportunity identified in **Unmanned Underwater Vehicles (UUVs)** and unattended sensors. **The current GenX unit capability** has an immediate market in the rapidly-growing UUV fleet.



Favourable regulatory environments will **accelerate commercial timelines for space and terrestrial defence applications**. Engaged with multiple end-users and platform developers for commercial deployment.



\$1m development grant secured (RHU)



Grant capital received for a mission-critical trial to validate flight heritage and unlock commercial pathways for the RHU.



Non-dilutive funding to advance RHU commercial readiness.



entX

entX